mesoblast

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy – CORRECTION

April 10, 2026 16:09 ET  | Source: Mesoblast Limited Working with Parent Project Muscular Dystrophy and the Duchenne Registry on…

16 hours ago

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

March 11, 2026 19:21 ET  | Source: Mesoblast Limited NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

1 month ago

Mesoblast Announces Changes to Board of Directors’ Leadership Roles

January 01, 2026 18:02 ET  | Source: Mesoblast Limited NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…

3 months ago

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

December 29, 2025 18:57 ET  | Source: Mesoblast Limited Mesoblast has option to draw down up to US$125 million by…

3 months ago